1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis

Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis

  • February 2014
  • -
  • Industry Standard Research
  • -
  • 59 pages

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports gives an overview of the current and future brain cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments.

What you will learn in this report:
How you can use this report:
- Identify and enhance commercial and development opportunities with an in-depth and current analysis of the global glioblastoma multiforme market
- Understand how products currently in development could impact this market and how large and small pharma is involved
- Assess the competition with an analysis and summary of companies playing in this space
- Brand Managers
- Portfolio Managers
- Research & Development
- Managed Markets

Companies Included:
Descriptions of product names, mechanism of actions (MOA), and highest development phase for the following companies:
- AbbVie
- Actelion Pharma
- Activartis
- Aduro Biotech
- Advantagene
- Agenus
- Amgen
- Angiochem
- Antisense Pharma
- Apogenix
- Archer Biosciences
- Arno Therapeutics
- Ascenta Therapeutics
- AstraZeneca (MedImmune)
- BristolMeyersSquibb
- Cell Therapeutics
- Celldex Therapeutics
- CytoVac A/S
- DelMar Pharma
- Dendreon
- Diffusion Pharma
- DNAtrix Inc
- Eisai
- Eli Lilly (Imclone)
- EMD Serono
- EnGenIC
- Erimos Pharma
- Genentech
- GW Pharma
- Immatics Biotechnologies
- ImmunoCellular Therapeutics
- Innocell Corp
- Lentigen
- Merck (Schering-Plough)
- Merck KGaA
- Northwest Biotherapeutics
- Novartis
- NovaRx
- Oncolytics Biotech
- Oncothyreon
- Oncovir Inc.
- Peregrine Pharma
- Plexxikon
- Roche
- Sangamo Biosciences
- Sanofi (Exelixis)
- Sanofi Aventis
- StemLine Therapeutics
- Tau Therapeutics
- Thallion Pharma
- Threshold Pharma
- To-BBB technologies BV
- Tocagen
- TVAX Biomedical
- Valycyte
- VBL Therapeutics
- Visualase Inc.

Table Of Contents

Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
Table of Contents

Copyright and Usage Guidelines ..3
Table of Acronyms ...4
Infographic ...5
Chapter 1 - Disease Overview ..6
Symptoms ..9
Prognosis and Survival .10
Incidence ..11
Risk Factors ..12
Chapter 2 - Commercial Rationale .13
High Unmet Need and Lack of Effective Therapies ..14
Treatment 15
Orphan Disease Status .18
Active Drug Development Field ...19
Chapter 3 - Environmental Analysis ...20
Major Markets Environmental Analysis ...21
Trial and Recruitment Environment .22
Regulatory Environment ..24
Competitive Product Landscape ..24
Pricing and Reimbursement Environment ...25
Emerging Markets Environmental Analysis .28
Trial and Recruitment Environment .29
Regulatory Environment ..31
Competitive Product Landscape ..32
Pricing and Reimbursement Environment ...32
Chapter 4 - Clinical Development Pipeline .34
RandD Trends in the Treatment of Glioblastoma Multiforme 35
Immunotherapeutic Vaccines ..37
Anti-Angiogenesis 38
Gene Therapy ...38
Cell Signaling Pathway Inhibitors .38
Cytotoxics .39
Recent Late Stage Failures ...40
Late Stage Development Pipeline 41
DC-Vax-L (DC-Vax-Brain), Northwest Biotherapeutics .42
Immuncell-LC, Green Cross Corp (formerly Innocell) ..43
Rindopepimut, Celldex Therapeutics ...43
ICT-107, ImmunoCellular Therapeutics ...46
TVI-Brain-1, TVAX Biomedical ..48
Early Stage Development Pipeline ...50
Chapter 5. The Clinical Trial Environment ..53
Citations .58
About Industry Standard Research 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

Related Market Segments :

Brain Cancer

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.